Lundbeck Reports Strong Revenue and EBITDA Growth
News related to:Lundbeck · 2 min read
VALBY, Denmark, Nov. 10, 2026 /CourierPR/ -- Lundbeck, a Danish pharmaceutical company, reported strong financial growth in the first nine months of 2026, with total revenue increasing by 13% when adjusted for exchange rates (CER) to DKK 20,191 million. This growth was driven by robust performance across all regions, with the United States, Europe, and International Operations all contributing to the overall increase.
In the United States, revenue grew by 18% CER to DKK 11,217 million, while in Europe, it rose by 9% CER to DKK 4,714 million. International Operations saw a more modest increase of 5% CER to DKK 4,000 million. The company's strategic brands, which account for 79% of total revenue, saw a 16% CER increase, with individual growth of 13% CER for Rexulti® and a striking 45% CER for Vyepti®. Brintellix®/Trintellix® and the Abilify LAI franchise saw more moderate growth, with 0% CER and 6% CER, respectively.
Lundbeck's earnings before interest, taxes, depreciation, and amortization (EBITDA) also saw significant growth, increasing to DKK 6,854 million, up 17% CER from the previous period. Adjusted EBITDA, which excludes one-time inventory build costs, reached DKK 7,026 million, a 19% CER increase. Excluding the one-time inventory build, EBITDA grew to DKK 6,440 million, up 10% CER, while adjusted EBITDA increased to DKK 6,612 million, up 12% CER.
The company's strong financial performance has led to an upward revision of its full-year guidance. Lundbeck now expects revenue to grow by 11% to 12% CER, up from the previous forecast of 7% to 9%. Adjusted EBITDA growth is now projected to be 15% to 19% CER, compared to the earlier guidance of 8% to 14%.
The company also announced several recent events, including the approval of Vyepti® in Japan, the completion of the DEEp SEA phase III clinical trial for bexicaserin, and the granting of Orphan Drug Designation to asedebart for the treatment of endogenous Cushing's syndrome. Additionally, Lundbeck will relocate its U.S. headquarters to Greater Boston, Massachusetts, establishing a global innovation hub in the region.